A new study by researchers at the Johns Hopkins University has found that second opinions did not change treatment choice among men diagnosed with low-risk prostate cancer.
Men often seek second opinions from urologists before they initiate treatment for their newly diagnosed prostate cancer. However, a new study by researchers at the Johns Hopkins University has found that second opinions did not change treatment choice or the person’s perception of the quality of care they receive, at least among low-risk men. Therefore, the value of these second opinions remains unknown.
For this study, published in the journal Cancer, 2386 men in the greater Philadelphia area, who were diagnosed with prostate cancer between 2012 and 2014, responded to survey questions. The survey asked the men if they had opted for a second opinion from a urologist following their diagnosis of prostate cancer, and the reasons for the second opinion. Following application of the relevant exclusion criteria, 2365 respondents remained in the analytical cohort.
Forty percent of the cohort said they had reached out for a second opinion, either because they wanted more information about their disease (50.8%) or wanted to be seen by the best doctor (46.3%). Second opinions, however, did not impact the final treatment decision or the perceived quality of cancer care. The authors found that men who were dissatisfied with their initial urologist were less likely to receive definitive treatment (odds ratio [OR], 0.49; 95% CI, 0.32-0.7). Men who were looking for additional information on their treatment were less likely to report satisfaction with their quality of cancer care (OR, 0.70; 95% CI, 0.49-0.99). The control cohort for this study was men who did not meet a urologist for a second opinion.
These study data can help inform oncologists and cancer organizations that encourage patients to seek a second opinion before treatment initiation, the objective being an improved understanding of their diagnosis and the ability to objectively weight the risks and benefits associated with their treatment. Especially among low-risk prostate cancer patients, second opinions could significantly impact decisions on treatment versus active surveillance. However, the study did not find an association between second opinions and treatment in low-risk men.
These results, if validated in other studies, justify additional investigation on how second opinions can contribute to increasing the value of cancer care, the authors concluded.
Reference
Radhakrishnan A, Grande D, Mitra N, Bekelman J, Stillson C, Pollack CE. Second opinions from urologists for prostate cancer: who gets them, why, and their link to treatment [published online November 7, 2016]. Cancer. doi: 10.1002/cncr.30412.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More